166 related articles for article (PubMed ID: 24252723)
21. Study of forced degradation behavior of enalapril maleate by LC and LC-MS and development of a validated stability-indicating assay method.
Bhardwaj SP; Singh S
J Pharm Biomed Anal; 2008 Jan; 46(1):113-20. PubMed ID: 17964751
[TBL] [Abstract][Full Text] [Related]
22. Identification and characterization of stressed degradation products of prulifloxacin using LC-ESI-MS/Q-TOF, MSn experiments: development of a validated specific stability-indicating LC-MS method.
Raju B; Ramesh M; Srinivas R; Raju SS; Venkateswarlu Y
J Pharm Biomed Anal; 2011 Nov; 56(3):560-8. PubMed ID: 21783336
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a novel stability-indicating HPLC method for the quantitative determination of eleven related substances in ezetimibe drug substance and drug product.
Luo Z; Deng Z; Liu Y; Wang G; Yang W; Hou C; Tang M; Yang R; Zhou H
Talanta; 2015 Jul; 139():67-74. PubMed ID: 25882410
[TBL] [Abstract][Full Text] [Related]
24. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of stress degradation products of febuxostat employing ultra-performance liquid chromatography-ultraviolet/photodiode array and liquid chromatography-mass spectrometry/time-of-flight studies.
Saha M; Bali A; Patra SR; Singh J
Rapid Commun Mass Spectrom; 2023 Jan; 37(2):e9423. PubMed ID: 36278931
[TBL] [Abstract][Full Text] [Related]
26. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.
Lee C; Park HK; Jeong H; Lim J; Lee AJ; Cheon KY; Kim CS; Thomas AP; Bae B; Kim ND; Kim SH; Suh PG; Ryu JH; Kang BH
J Am Chem Soc; 2015 Apr; 137(13):4358-67. PubMed ID: 25785725
[TBL] [Abstract][Full Text] [Related]
27. RP-LC Method Development and Validation for Dasatinib Forced Degradation Study: Isolation and Structural Characterization by NMR and HRMS.
Kavitapu DR; Murty JNSRC; Maruthapillai A; Senadi GC; Mahapatra S
J Chromatogr Sci; 2024 Apr; 62(4):347-355. PubMed ID: 37340779
[TBL] [Abstract][Full Text] [Related]
28. Impurity profiling and stability-indicating method development and validation for the estimation of assay and degradation impurities of midostaurin in softgel capsules using HPLC and LC-MS.
Lakka NS; Kuppan C; Ravinathan P
Biomed Chromatogr; 2021 Dec; 35(12):e5222. PubMed ID: 34331472
[TBL] [Abstract][Full Text] [Related]
29. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
Beebe K; Mollapour M; Scroggins B; Prodromou C; Xu W; Tokita M; Taldone T; Pullen L; Zierer BK; Lee MJ; Trepel J; Buchner J; Bolon D; Chiosis G; Neckers L
Oncotarget; 2013 Jul; 4(7):1065-74. PubMed ID: 23867252
[TBL] [Abstract][Full Text] [Related]
30. Isolation, Characterization, and Toxicity Study of Stress Degradation Products of Pranlukast Hydrate.
Prajapati KJ; Kothari CS
Chem Res Toxicol; 2022 Jul; 35(7):1206-1219. PubMed ID: 35731702
[TBL] [Abstract][Full Text] [Related]
31. Development of a stability- indicating HPLC method for simultaneous determination of ten related substances in vonoprazan fumarate drug substance.
Luo Z; Liu A; Liu Y; Wang G; Chen X; Wang H; Li M; Zhang H; Qiu Y; Zhai H
J Pharm Biomed Anal; 2018 Feb; 149():133-142. PubMed ID: 29112902
[TBL] [Abstract][Full Text] [Related]
32. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
[TBL] [Abstract][Full Text] [Related]
33. Characterization, HPLC method development and impurity identification for 3,4,3-LI(1,2-HOPO), a potent actinide chelator for radionuclide decorporation.
Liu M; Wang J; Wu X; Wang E; Abergel RJ; Shuh DK; Raymond KN; Liu P
J Pharm Biomed Anal; 2015 Jan; 102():443-9. PubMed ID: 25459944
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.
Yuzefovych Y; Blasczyk R; Huyton T
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2338-48. PubMed ID: 26112988
[TBL] [Abstract][Full Text] [Related]
35. A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90).
Shahinas D; Folefoc A; Taldone T; Chiosis G; Crandall I; Pillai DR
PLoS One; 2013; 8(9):e75446. PubMed ID: 24098696
[TBL] [Abstract][Full Text] [Related]
36. RP-HPLC separation and ESI-MS, 1H, and 13C NMR characterization of forced degradants including process related impurities of carisbamate: method development and validation.
Rao RN; Ramakrishna K; Sravan B; Santhakumar K
J Pharm Biomed Anal; 2013 Apr; 77():49-54. PubMed ID: 23376724
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of Prothionamide degradation impurities by mass spectrometry, NMR spectroscopy, and ultra high performance liquid chromatography method development.
Baksam VK; Saritha N; Mohan SK; Shandilya S; Kumar P
J Sep Sci; 2021 May; 44(10):2078-2088. PubMed ID: 33733566
[TBL] [Abstract][Full Text] [Related]
38. Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate.
Chitturi SR; Somannavar YS; Peruri BG; Nallapati S; Sharma HK; Budidet SR; Handa VK; Vurimindi HB
J Pharm Biomed Anal; 2011 Apr; 55(1):31-47. PubMed ID: 21316175
[TBL] [Abstract][Full Text] [Related]
39. Stability-indicating method development and validation for quantitative estimation of assay and organic impurities of antiviral drug baloxavir marboxil in drug substance and pharmaceutical dosage form using HPLC and LC-MS methods.
Nagulancha BR; Lakka NS; Vandavasi KR
Biomed Chromatogr; 2023 Aug; 37(8):e5644. PubMed ID: 37052118
[TBL] [Abstract][Full Text] [Related]
40. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.
Chan CT; Paulmurugan R; Gheysens OS; Kim J; Chiosis G; Gambhir SS
Cancer Res; 2008 Jan; 68(1):216-26. PubMed ID: 18172314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
